Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Current Assets (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Current Assets readings, the most recent being $1.0 billion for Q4 2025.

  • Quarterly Current Assets rose 182.84% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, up 182.84% year-over-year, with the annual reading at $1.0 billion for FY2025, 182.84% up from the prior year.
  • Current Assets hit $1.0 billion in Q4 2025 for Terns Pharmaceuticals, up from $300.3 million in the prior quarter.
  • Across five years, Current Assets topped out at $1.0 billion in Q4 2025 and bottomed at $142.6 million in Q2 2022.
  • Average Current Assets over 5 years is $291.2 million, with a median of $268.9 million recorded in 2023.
  • The largest annual shift saw Current Assets dropped 23.69% in 2022 before it surged 182.84% in 2025.
  • Terns Pharmaceuticals' Current Assets stood at $166.9 million in 2021, then skyrocketed by 70.84% to $285.2 million in 2022, then fell by 6.23% to $267.4 million in 2023, then skyrocketed by 35.4% to $362.1 million in 2024, then surged by 182.84% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for TERN's Current Assets are $1.0 billion (Q4 2025), $300.3 million (Q3 2025), and $319.0 million (Q2 2025).